Safinamide mesylate

CAS: 202825-46-5

Ref. 3D-FS101887

Información del producto

• Nombre: Safinamide mesylate
• Sinónimos: (S)-2-[[4-[(3-Fluorobenzyl)oxy]benzyl]amino]propanamide methanesulfonate, EMD 1195686 mesylate, FCE-28073(R-isomer), Fce-26743, Nw-1015, N~2~-{4-[(3-fluorobenzyl)oxy]benzyl}-D-alaninamide methanesulfonate, Pnu-151774E, Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, methanesulfonate (1:1), Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)-, monomethanesulfonate, Propanamide, 2-[[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino]-, (S)-, monomethanesulfonate, Safinamide mesilate, Safinamide methanesulfonate, Xadago

Descripción

Safinamide mesylate is a drug that has been approved for the treatment of Parkinson's disease in Japan. It is an inhibitor of monoamine oxidase-B (MAO-B) and dopamine beta-hydroxylase, which are enzymes that break down dopamine. Safinamide mesylate has a chemical structure that reacts with hydrochloric acid to produce hydrogen gas and an acid formation. The drug also inhibits the conversion of dopamine to dihydroxyphenylacetic acid (DOPAC), which causes an accumulation of dopamine in the brain. Safinamide mesylate is metabolized by hydroxylation, deamination, and oxidation; its metabolites are excreted through urine. Pharmacokinetic studies have shown that safinamide mesylate has linear pharmacokinetics after intravenous injection or oral administration. Analysis by high performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) has revealed the presence of two metabolites

• Marca: Biosynth

Propiedades químicas

• Peso molecular: 398.45 g/mol
• Fórmula: C₁₇H₁₉FN₂O₂•CH₄O₃S
• Pureza: Min. 95%
• Color/Forma: White To Off-White Solid